Standard Ultrasound Guidance vs. New Needle-steering Device in Subclavian Venous Catheterization (NEEDLEVISIO2)

February 10, 2026 updated by: Centre Hospitalier Universitaire de Nīmes

Ultrasound-guided Subclavian Venous Catheterization. A Randomized, Single-blind, Controlled Superiority Trial Comparing Standard Ultrasound Guidance and a New Needle-steering Device

Up to two-thirds of intensive care unit patients require central venous catheterization for which ultrasound-guided placement is now recommended. In this context, the team performed a prospective randomized simulation trial on a mannequin ("reduced torso model"), to compare the standard ultrasound guidance technique with an ultrasound-guided technique assisted by a new needle-steering device. The preliminary results show a statistically significant improvement in subclavian venipuncture (shorter success time, fewer multiple skin punctures, fewer punctures of the posterior wall of the subclavian vein and needle redirection, greater comfort) and argue for a clinical trial to test the performance of this new device in situation with intensive care unit patients.

The hypothesis is that the needle-steering device will result in a better success rate of subclavian venous cannulation, at first puncture, compared with the conventional ultrasound-guided technique.

Study Overview

Detailed Description

Central venous catheterization is required in up to two-thirds of intensive care unit patients. Ultrasound-guided placement is now recommended over the "blind" technique to decrease the risk of mechanical complications and duration of the procedure. Although the subclavian site is recommended as first-line because of a lower risk of catheter-related infection and thrombosis (than with internal jugular and femoral sites), this approach is underused (< 20% of regular users). There is also a very low use of ultrasound guidance for subclavian catheterization (< 30% of cases), due to technical difficulties such as more complex visualization of the needle.

New magnetic devices theoretically allow better visualization of the needle, a higher success rate and a lower complication rate. In this context, the team performed a prospective randomized simulation trial on a phantom ("reduced torso model"), comparing the standard ultrasound guidance technique with an ultrasound-guided technique assisted by a new needle-steering device in subclavian central venous catheterization (study in progress). The results of this study show a statistically significant improvement in subclavian venipuncture (shorter success time, fewer multiple skin punctures, fewer punctures of the posterior wall of the subclavian vein and needle redirection, greater comfort).

These preliminary results argue for a clinical trial of the practical performance of this new device in intensive care unit patients.

The hypothesis is that the needle-steering device will result in a higher success rate of subclavian venous cannulation at first puncture compared with the conventional ultrasound guidance technique.

Study Type

Interventional

Enrollment (Actual)

124

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nîmes, France, 30029
        • CHU de Nîmes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Any resuscitation patient requiring subclavian venous catheterization.
  • Patients or representatives must have given free, informed consent and signed the consent form or patient included in an emergency situation
  • Patients must be affiliated to/or beneficiary of a health insurance scheme.
  • All patients must be adults (≥18 years of age).

Exclusion Criteria:

  • Moribund patients
  • Patients with severe primary or secondary hemostasis disorders (Pq < 50 G/L or TP < 30%, or INR > 2).
  • Patients with a PaO2/FiO2 ratio < 100 mmHg in mechanically ventilated patients (invasive or non-invasive ventilation).
  • Patients with a precarious or unstable respiratory status and significant risk of barotrauma
  • Patients for whom it is difficult to visualize the subclavian veins bilaterally (left and right) during ultrasound pre-screening
  • Patients with a malformation/deformity of the subclavian region (congenital or acquired: history of surgery/cervical trauma)
  • Body mass index < 15 kg/m² ou > 40 kg/m²
  • Local infection at the puncture site
  • Thrombosis of the subclavian or axillary vein
  • Patients participating in a category 1 defined RIPH involving subclavian central venous line placement.
  • Patients under court protection, guardianship or curatorship.
  • Pregnant, parturient or breastfeeding women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard ultrasound guidance for subclavian venipuncture
62 patients undergoing the usual standard ultrasound guidance technique for subclavian venipuncture
Experimental: Subclavian venipuncture using the needle-steering device
62 patients undergoing subclavian venipuncture using the needle-steering device
  1. Navigation software is implemented in an ultrasound machine.
  2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used
  3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.
  4. Real time needle guidance on the ultrasound screen during the puncture.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Successful catheter insertion at first skin puncture: Control group
Time Frame: Day 0

The main objective is to compare the success rate of subclavian venous cannulation at first puncture between the conventional ultrasound guidance technique and ultrasound guidance assisted by a needle-steering device.

Successful subclavian venous cannulation (success is defined as catheter insertion at first skin puncture).

YES/NO

Day 0
Successful catheter insertion at first skin puncture: Experimental group
Time Frame: Day 0

The main objective is to compare the success rate of subclavian venous cannulation at first puncture between the conventional ultrasound guidance technique and ultrasound guidance assisted by a needle-steering device.

Successful subclavian venous cannulation (success is defined as catheter insertion at first skin puncture).

YES/NO

Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
A. Number of skin punctures required before successful central venous catheterism: Control group
Time Frame: Day 0
Median number of skin punctures required before successful central venous catheterism. Success is defined as catheter insertion.
Day 0
A. Number of skin punctures required before successful central venous catheterism: Experimental group
Time Frame: Day 0
Median number of skin punctures required before successful central venous catheterism. Success is defined as catheter insertion.
Day 0
B. Complication rate. All causes, composite score: Control group
Time Frame: Day 0
Onset of at least one complication due to venous puncture. Complications including pneumothorax, arterial puncture, hematoma, malpositioning or puncture failure will all be recorded.
Day 0
B. Complication rate. All causes, composite score: Control group
Time Frame: Hour 24
Onset of at least one complication within 24 of venous puncture. Complications including pneumothorax, arterial puncture, hematoma, malpositioning or puncture failure will all be recorded.
Hour 24
B. Complication rate. All causes, composite score: Experimental group
Time Frame: Day 0
Onset of at least one complication due to venous puncture. Complications including pneumothorax, arterial puncture, hematoma, malpositioning or puncture failure will all be recorded.
Day 0
B. Complication rate. All causes, composite score: Experimental group
Time Frame: Hour 24
Onset of at least one complication within 24 of venous puncture. Complications including pneumothorax, arterial puncture, hematoma, malpositioning or puncture failure will all be recorded.
Hour 24
C. Pneumothorax within 24 hours of venous puncture: Control group
Time Frame: Hour 24

Data collection using a standardized online electronic Case Report Form. Clinical history + frontal chest X-rays taken within one hour of puncture AND at H12-24 +/- ultrasound or computed tomography scan according to clinical or diagnostic doubt (examinations carried out at the discretion of the physicians).

The number and percentage of patients with pneumothorax will be recorded.

Hour 24
C bis. Drainage required for pneumothorax within 24 hours of venous puncture: Control group
Time Frame: Hour 24
Data collection using a standardized online electronic Case Report Form. YES/NO
Hour 24
C. Pneumothorax within 24 hours of venous puncture: Experimental group
Time Frame: Hour 24

Data collection using a standardized online electronic Case Report Form Clinical history + frontal chest X-rays taken within one hour of puncture AND at 12-24 hours +/- ultrasound or computed tomography scan according to clinical or diagnostic doubt (examinations carried out at the discretion of the physicians).

The number and percentage of patients with pneumothorax will be recorded.

Hour 24
C bis. Drainage required for pneumothorax within 24 hours of venous puncture: Experimental group
Time Frame: Hour 24
Data collection using a standardized online electronic Case Report Form YES/NO
Hour 24
D. Arterial puncture within 24 hours of venous puncture: Control group
Time Frame: Day 0
YES / NO Data collection using a standardized online electronic Case Report Form. Any arterial punctures during the procedure will be recorded in numbers and percentages by an independent investigator, present during the procedure and therefore aware of technique used.
Day 0
D. Arterial puncture within 24 hours of venous puncture: Experimental group
Time Frame: Day 0
YES / NO Data collection using a standardized online electronic Case Report Form. Any arterial punctures during the procedure will be recorded in numbers and percentages by an independent investigator, present during the procedure and therefore aware of technique used.
Day 0
E. Hematoma or hemorrhage Grade 3 or over within 24 hours of venous puncture: Control group
Time Frame: Hour 24

YES / NO. Data collection using a standardized online electronic Case Report Form.

Clinical history + frontal chest X-rays taken within one hour of puncture AND at H12-24 +/- ultrasound or CT scan according to clinical point of call or diagnostic doubt (examinations carried out according to the choice of the department's physicians).

Within 24 hours, occurrence of hematoma or hemorrhage grade ≥ 3 (specify whether a therapeutic intervention is required - according to the definition below - or transfusion for intrathoracic bleeding). The occurrence of grade ≥ 3 hematoma or hemorrhage will be established according to the definition of "Common Terminology Criteria for Adverse Events (CTCAE) v5.0": indication for transfusion or invasive intervention (grade 3), need for urgent intervention or alteration of vital prognosis (grade 4), or death (grade 5).

Hour 24
E. Hematoma or hemorrhage Grade 3 or over within 24 hours of venous puncture: Experimental group
Time Frame: Hour 24

YES / NO. Data collection using a standardized online electronic Case Report Form .

Clinical history + frontal chest X-rays taken within one hour of puncture AND at H12-24 +/- ultrasound or CT scan according to clinical point of call or diagnostic doubt (examinations carried out according to the choice of the department's physicians).

Within 24 hours, occurrence of hematoma or hemorrhage grade ≥ 3 (specify whether a therapeutic intervention is required - according to the definition below - or transfusion for intrathoracic bleeding). The occurrence of grade ≥ 3 hematoma or hemorrhage will be established according to the definition of "Common Terminology Criteria for Adverse Events (CTCAE) v5.0": indication for transfusion or invasive intervention (grade 3), need for urgent intervention or alteration of vital prognosis (grade 4), or death (grade 5).

Hour 24
F. Malpositioned catheter seen on the X-ray within 1 hour of venous puncture: Control group
Time Frame: Hour 24

YES / NO. Data collection using a standardized online electronic Case Report Form .

Front thoracic radiograph (systematically within one hour of puncture) puncture): "Sweet Spot" technique (approximation of the atriocaval junction, a rectangle in which the position of the lower end of the central venous line: between the lower third of the superior vena cava and the inferior lower edge of the right atrium (located by the cardiophrenic angle). Malpositioning will be recorded as numbers and percentages.

Hour 24
F. Malpositioned catheter seen on the X-ray within 1 hour of venous puncture: Experimental group
Time Frame: Hour 24

YES / NO. Data collection using a standardized online electronic Case Report Form.

Front thoracic radiograph (systematically within one hour of puncture) puncture): "Sweet Spot" technique (approximation of the atriocaval junction, a rectangle in which the position of the lower end of the central venous line: between the lower third of the superior vena cava and the inferior lower edge of the right atrium (located by the cardiophrenic angle). Malpositioning will be recorded as numbers and percentages.

Hour 24
G. Time taken from first skin puncture to successful catheter insertion: Control group
Time Frame: Day 0
In seconds
Day 0
G. Time taken from first skin puncture to successful catheter insertion: Experimental group
Time Frame: Day 0
In seconds
Day 0
H. Failure rate: Control group
Time Frame: Day 0

Percentage of failures. After three failed punctures, the technique is considered as a failure. Data collection using a standardized online electronic Case Report Form.

The number of skin punctures will be counted. The criterion "failure" will be retained after 3 unsuccessful skin punctures.

This requires a change of insertion site and withdrawal from the study. The other complication criteria mentioned above will still be recorded and analyzed but the time will not be collected (criterion G).

Day 0
H. Failure rate: Experimental group
Time Frame: Day 0

Percentage of failures. After three failed punctures, the technique is considered as a failure.Percentage of failures. After three failed punctures, the technique is considered as a failure. Data collection using a standardized online electronic Case Report Form.

The number of skin punctures will be counted. The criterion "failure" will be retained after 3 unsuccessful skin punctures.

This requires a change of insertion site and withdrawal from the study. The other complication criteria mentioned above will still be recorded and analyzed but the time will not be collected (criterion G).

Day 0

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Age
Time Frame: Day 0
In years
Day 0
Height
Time Frame: Day 0
In centimeters
Day 0
Weight
Time Frame: Day 0
In kilos
Day 0
Gender
Time Frame: Day 0
Male/Female
Day 0
Simplified Severity Index II score
Time Frame: Hour 24
The SSI II score ( Simplified Severity Index II) is a score used to assess a patient's severity, and is one of the scores used in intensive care and resuscitation. The parameters to be taken into account are the most severe ones collected during the 24 hours following admission to intensive care.
Hour 24
Sequential Organ Failure Assessment score
Time Frame: Day 0
The Sequential Organ Failure Assessment (SOFA) score is a scoring system that assesses the performance of several organ systems in the body (neurologic, blood, liver, kidney, and blood pressure/hemodynamics) and assigns a score based on the data obtained in each category.
Day 0
Puncture on right side ?
Time Frame: Day 0
YES/NO
Day 0
Patient unconscious ?
Time Frame: Day 0
YES/NO (absence of contact and movement at the time of puncture)
Day 0
Positive End Expiratory Pressure
Time Frame: Day 0
In cm H²O
Day 0
Indication for central venous catheter : Shock / vasopressor support
Time Frame: Day 0
YES/NO
Day 0
Indication for central venous catheter : nutrition
Time Frame: Day 0
YES/NO
Day 0
Indication for central venous catheter : Administration of venotoxic drugs
Time Frame: Day 0
YES/NO
Day 0
Indication for central venous catheter : Poor venous capital
Time Frame: Day 0
YES/NO
Day 0
Indication for central venous catheter : Vascular filling
Time Frame: Day 0
YES/NO
Day 0
Indication for central venous catheter : Repeated blood sampling
Time Frame: Day 0
YES/NO
Day 0
Indication for central venous catheter : Central venous pressure monitoring
Time Frame: Day 0
YES/NO
Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 16, 2024

Primary Completion (Actual)

December 26, 2025

Study Completion (Actual)

December 26, 2025

Study Registration Dates

First Submitted

September 5, 2023

First Submitted That Met QC Criteria

September 18, 2023

First Posted (Actual)

September 22, 2023

Study Record Updates

Last Update Posted (Actual)

February 11, 2026

Last Update Submitted That Met QC Criteria

February 10, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NIMAO/2021-1/NB-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The analysis of the data will be carried out by the BESPIM service of the CHU of Nîmes.

Within one year after the end of the research or its interruption, a final report will be established and signed by the sponsor and the investigator. This report will be made available to the competent authority. The sponsor will transmit the results of the research in the form of a summary of the final report to the CPP (Comité de Protection des Personnes) and, if necessary, to the ANSM within one year after the end of the research.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Central Venous Catheterization

Clinical Trials on Subclavian venipuncture for catheter placement using the needle-steering device

Subscribe